Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
EVALUATION OF THE LOSARTAN IN HEMODIALYSIS (ELHE) STUDY
Autore:
SARACHO R; MARTINMALO A; MARTINEZ I; ALJAMA P; MONTENEGRO J;
Indirizzi:
HOSP GALDAKAO,SERV NEFROL,BARRIO LABEAGA S-N USANSOLO 48960 VIZCAYA SPAIN HOSP REINA SOFIA,SERV NEPHROL CORDOBA SPAIN
Titolo Testata:
Kidney international
, volume: 54, anno: 1998, supplemento:, 68
pagine: 125 - 129
SICI:
0085-2538(1998)54:<125:EOTLIH>2.0.ZU;2-2
Fonte:
ISI
Lingua:
ENG
Soggetto:
CONVERTING-ENZYME-INHIBITORS; FLUX MEMBRANE DIALYSIS; ANAPHYLACTOID REACTIONS; RISK-FACTORS; BRADYKININ; TOLERABILITY; HYPERTENSION; SAFETY;
Keywords:
HIGH BLOOD PRESSURE; HEMODIALYSIS; ANAPHYLACTOID REACTION; LOSARTAN; DIALYSIS MEMBRANES;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
12
Recensione:
Indirizzi per estratti:
Citazione:
R. Saracho et al., "EVALUATION OF THE LOSARTAN IN HEMODIALYSIS (ELHE) STUDY", Kidney international, 54, 1998, pp. 125-129

Abstract

Angiotensin converting enzyme inhibitors (ACEIs) have been shown to be effective in the treatment of dialysis patients with high blood pressure, however, they also have been associated with anaphylactoid reactions at the start of dialysis, when they have been used concomitantly with AN69 membranes. A multicenter, open six-month study was designed to test the tolerability and efficacy of losartan as antihypertensive in patients under hemodialysis (HD), with particular emphasis on the appearance of anaphylactoid reactions. HD patients with systolic blood pressure (SBP) levels greater than or equal to 140 and/or diastolic blood pressure (DBP) greater than or equal to 90 mm Hg, previously nontreated, treated but uncontrolled, or treated with a poor tolerability, were included. The study performed three controls: baseline, at month 3, and at study completion. DBP and SEP levels were measured on the six HD sessions previous to the three visits in addition to biochemical and hematology measurements. Four hundred and six patients were included. The mean age was 55 years, 42% were women, and 23.6% of the patients were dialyzed with AN69 membranes. There was a significant reduction in pre- and postdialysis SEP and DBP at three and six months. Fifteen patients discontinued the study due to adverse reactions related to losartan, and in seven of them the adverse reaction was hypotension. Only two patients have reported a possible anaphylactoid reaction on treatment with AN69, in one of them the HD session had to be stopped andlosartan was discontinued. On the contrary, nine patients with a history of previous anaphylactoid reaction, with ACEIs and AN69, have not shown this complication with losartan and AN69. We conclude that losartan is a well tolerated antihypertensive by HD patients, with a very low incidence of adverse reactions, and a lower prevalence of anaphylactoid reactions than those detected with ACEIs and AN69.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 17/01/21 alle ore 18:21:59